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Abstract
In their letter to the Editor in this issue, Kolstoe and Carpenter challenge a core aspect of our recently published
case study of research approvals [BMC Medical Ethics 20:7] by arguing that we conflate research ethics with
governance and funding processes. Amongst the key concerns of the authors are: 1) that our paper exemplifies a
typical conflation of concepts such as governance, integrity and ethics, with significant consequences for claims
around the responsibility and accountability of the organisations involved; 2) that, as a consequence of this
conflation, we misrepresent the ethics review process, including in fundamental aspects such as the ethics
approval-opinion distinction; 3) that it is difficult to see scope for greater integration of processes such as applying
for funding, research approvals, Patient and Public Involvement, etc., as suggested by us. Here we present an
alternative point of view towards the concerns raised.
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Dear Editor,
Thank you for the opportunity to respond to the letter
of Kolstoe and Carpenter [1] about our paper “Research
approvals iceberg: how a ‘low-key’ study in England
needed 89 professionals to approve it and how we can
do better” [2]. We are grateful to our colleagues for the
time and thought they have taken to write a formal re-
sponse. We are also grateful to BMC Medical Ethics for
providing a platform for debating an issue with pro-
found, yet often neglected, consequences for our science
and knowledge. We appear to share crucial common
ground with the authors in agreeing that the ethics and
governance processes are indispensable for good
research, that they can be “laborious and highly frustrat-
ing”, and that we have a responsibility to improve them.
Such agreement about the fundamentals will hopefully
further the debate constructively, even if, most likely, we
agree to disagree.
Ethics vs. governance, or ethics with governance –
depends on where you sit
The main point in our colleagues’ criticism is that “the
paper contains a key misunderstanding by conflating dif-
ferent systems and processes”, namely around research
ethics, on the one hand, and research governance, on
the other. The authors note our acknowledgement of
the distinction as “extremely important” but see our de-
cision to consider the processes jointly as disappointing
and “a significant mistake”. They also lay out helpfully
for readers differences between research ethics and
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research governance, which we had only given in broad
outlines.
This may be an occasion where the two sides agree on
the facts, but not on how to combine and/or evaluate
them. We agree fully with our colleagues that the
processes have ‘slightly different philosophical and prac-
tical contribution to the conduct of “good science”’, per-
haps less with their sharper subsequent rephrasing that
“Research governance is related to research ethics, but
operates under a different philosophy and using different
methods”. We believe that the processes are significantly
intertwined and interdependent even if, from certain
perspectives, sufficiently different and distinct.
In our experience, governance approvals generally re-
quire a preceding favourable ethics committee opinion.
The processes are not only intertwined but may become
locked in a temporary Catch 22. For instance, the ethics
committee may want to know where a study would be
conducted, while the potential sites are asking for a
favourable ethical opinion before committing to hosting
it. Furthermore, the electronic IRAS system (Integrated
Research Application System) enables both ethics review
submissions and site-specific governance approvals and
much of the study documentation, sponsor and re-
searcher credentials submitted, within or outside IRAS,
are identical.
Our main rationale for discussing the processes of eth-
ics and governance approvals together related, however,
to their place in the trajectory of a research study from a
researcher’s perspective. These processes represent a dis-
tinct part of that trajectory, involving tasks and out-
comes which are, to a significant degree, qualitatively
different to those involved in applying for funding, col-
lecting data, analysing data, writing up papers, etc. To
us, this is a phase we can usefully call one of “study ap-
provals” (we will return to the term “approval” below).
We argue that most researchers are attuned to the
broader similarities that define work within this phase
rather than to fine, precise distinctions between the vari-
ous components of it.
Of course, from the perspective of a representative of
an ethics committee, or a sponsor, or a local R&D office,
their work is very distinct from that done in “other” or-
ganisations. We accept that one of the unfortunate con-
sequences of wanting to illustrate the whole that results
from badly fitting parts is that efficient, even exemplary,
parts of the system may be perceived to be just as
“guilty” of the overall burden as the less efficient ones.
Approval or opinion? One way or the other, we
will do what it says
In addition to the choice of viewing ethics and govern-
ance approvals in tandem, our colleagues have chal-
lenged the use of the word “approvals” when it comes to
the outcome of ethics review processes. They point out
that the accurate term is “opinion”. The authors are
completely right about the precise technical vocabulary
(which we also remember from correspondence with
ethics committees). However, we do not think that the
standard connotations of the word “opinion” (or at least
standard in a democratic world), such as sufficient flexi-
bility in whether you follow it or not, apply in the con-
text of research ethics committee opinions.
In the world of research, an ethics committee opinion
is, for all intents and purposes, impossible to ignore. It is
inconceivable in our day, age and part of the world to
proceed with a study in spite of an unfavourable opinion
by an ethics committee. This can only happen in secrecy,
without any chance for the study findings being pub-
lished in respectable journals, and with the researchers
risking every consequence of being accused of scientific
and/or ethical misconduct. We take the practical impli-
cations of an ethics committee opinion as justifying our
use of the term “approvals”.
It is complex enough, why make it extra complex?
The final point we will address concerns the critique of
one of our proposals for “where next”, namely around
bringing closer together ethics and governance approvals
and aspects of processes around grant applications and
reporting; PPI (Patient and Public Involvement); dissem-
ination, impact and public engagement and various
other outward-facing research activities. Our colleagues
have perceived this proposal as ignoring the distinctive-
ness of phases in research and exacerbating the confla-
tion they have tried to illuminate. To clarify the latter
point, we have in no way included those processes in
our estimates of approvals burden. We argued that they
have areas of overlapping concerns and documentation
and that there is value in their closer integration in the
future.
Our proposal is for a dynamic outward-facing profile
of a research study which grows and changes with time,
is accessed by different stakeholders at different stages of
the work, enables efficient documentation review and
sharing, and supports the goals of transparency and ac-
countability. It is beyond the scope of this brief letter to
expand on such a vision. Its success or otherwise is also
an empirical rather than theoretical matter, and we hope
to see prototype platforms in the not too distant future.
Eternal vigilance
There is a saying that the price of a metaphor is eternal
vigilance, which makes us offer the following one cau-
tiously. The position of a health research study relative
to the multiple stakeholders granting it the green light
to proceed/ enabling its progress is similar to that of a
child under the care of multiple providers.
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As researchers, we are perhaps like the parents of a
child needing routine healthcare, fearful of its well-
being, feeling its impact on our well-being, and (over-
)sensitive to the lack of clear pathways and the failure of
communication and coordination between services.
As people who, for the purposes of this debate, inhabit
mostly their roles of research ethics committee chairs,
the authors are perhaps like healthcare providers in one
of the many teams caring for the child, trying hard to
support both the patient and us, and (over-)sensitive to
the value of clear boundaries and the associated alloca-
tion of responsibility and accountability.
The tension will always be there, but we hope that this
response represents an opportunity to reduce it in posi-
tive and productive ways.
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